Role of drug delivery technologies in the success of COVID-19 vaccines: a perspective

Langer, Robert; Cullis, Pieter R.; Merkel, Olivia M.; Prausnitz, Mark R.; Gomaa, Yasmine; Nogueira, Sara S.; Kumeria, Tushar

doi:10.1007/s13346-022-01146-1

Cited by 32 publications

(18 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, the most critical measures to prevent and control the transmission of multiple variants such as Delta and Omicron remain to improve vaccination coverage, and there is a need to test the efficacy of vaccine cocktails against emerging variants, including Omicron ( 193 ), however, in-depth studies are needed to achieve long-term immunity. Besides, the COVID-19 vaccine or drug delivery system based on new materials such as nanoparticles will be an important research direction ( 194 ). The very important role of spike protein and RBD in protective humoral immunity induced by T-cell responses and neutralizing antibodies during SARS-CoV-2 infection provides an important direction for the development of new vaccines and drugs.…”

Section: Discussionmentioning

confidence: 99%

Uncovering the information immunology journals transmitted for COVID-19: A bibliometric and visualization analysis

et al. 2022

View full text Add to dashboard Cite

BackgroundSince the global epidemic of the coronavirus disease 2019 (COVID-19), a large number of immunological studies related to COVID-19 have been published in various immunology journals. However, the results from these studies were discrete, and no study summarized the important immunological information about COVID-19 released by these immunology journals. This study aimed to comprehensively summarize the knowledge structure and research hotspots of COVID-19 published in major immunology journals through bibliometrics.MethodsPublications on COVID-19 in major immunology journals were obtained from the Web of Science Core Collection. CiteSpace, VOSviewer, and R-bibliometrix were comprehensively used for bibliometric and visual analysis.Results1,331 and 5,000 publications of 10 journals with high impact factors and 10 journals with the most papers were included, respectively. The USA, China, England, and Italy made the most significant contributions to these papers. University College London, National Institute of Allergy and Infectious Diseases, Harvard Medical School, University California San Diego, and University of Pennsylvania played a central role in international cooperation in the immunology research field of COVID-19. Yuen Kwok Yung was the most important author in terms of the number of publications and citations, and the H-index. CLINICAL INFECTIOUS DISEASES and FRONTIERS IN IMMUNOLOGY were the most essential immunology journals. These immunology journals mostly focused on the following topics: “Delta/Omicron variants”, “cytokine storm”, “neutralization/neutralizing antibody”, “T cell”, “BNT162b2”, “mRNA vaccine”, “vaccine effectiveness/safety”, and “long COVID”.ConclusionThis study systematically uncovered a holistic picture of the current research on COVID-19 published in major immunology journals from the perspective of bibliometrics, which will provide a reference for future research in this field.

show abstract

Section: Discussionmentioning

confidence: 99%

Uncovering the information immunology journals transmitted for COVID-19: A bibliometric and visualization analysis

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Author details 1 Nakajima Medical Clinic, 1-8-3 Mikagenakamachi, Higashinada-ku, Kobe 658-0054, Japan. 2 Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan. 3 Division of Bioresource Research and Development, Department of Social/Community Medicine and Health Science, Kobe University Graduate School of Medicine, 1-5-1 Minatojimanakamachi, Chuo-ku, Kobe 650-0047, Japan.…”

Section: Author Contributionsmentioning

confidence: 99%

“…Various COVID-19 therapeutic agents have been developed. At the same time, vaccines for preventing COVID-19 have also been developed at a rapid pace [ 2 ]. Since clinical trials of vaccines evaluate immunogenicity in healthy individuals, immunogenicity in patients with concurrent diseases is not well understood.…”

Section: Introductionmentioning

confidence: 99%

Inhaled corticosteroids do not affect the antibody titer against the SARS-CoV-2 spike protein in BNT162b2 mRNA vaccinated patients

Nakajima¹,

Nagano

Miyata

et al. 2022

Allergy Asthma Clin Immunol

View full text Add to dashboard Cite

Objectives Oral corticosteroids reduce the antibody titer of the BNT162b2 mRNA vaccine against SARS-CoV-2. To date, the effect of inhaled corticosteroids on antibody titers is unknown. Study design The design of this study is retrospective study. Methods We analyzed the relationship between the clinical features and total antibody titers against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein in 320 subjects who had never been infected with Coronavirus disease 2019 (COVID-19) and were vaccinated the second time with the BNT162b2 mRNA vaccine between October 1 to December 28, 2021. Results Of the 320 subjects, 205 were treated with inhaled corticosteroids. The median antibody titer of patients treated with inhaled corticosteroids was 572 U/mL, which was significantly higher than that of patients treated without inhaled corticosteroids (454U/mL, P = 0.00258). The median antibody titers of smokers, men, and patients aged 65 years and over, were 315.5 U/mL, 385 U/mL, and 425.5 U/mL, respectively. These results are significantly lower than those of patients who never smoked, women, and patients aged less than 64 years (582 U/mL [P < 0.0001], 682.5 U/mL [P < 0.0001], and 717 U/mL [P < 0.0001], respectively). The multivariate analysis revealed that females and age were independent antibody titer-reducing factors (P = 0.0001 and P < 0.0001, respectively). Conclusions The use of inhaled corticosteroids did not reduce the antibody titer against SARS-CoV-2 spike protein. Clinicians should continue treatment with inhaled corticosteroids if indicated.

show abstract

“…Now known as lipid nanoparticles, they have been developed into regularly used drug delivery devices. 11 While Drs. Cullis and Langer were continuing their research, Drs.…”

Section: Introductionmentioning

confidence: 99%

Development of the mRNA vaccines to prevent COVID-19

Utley¹,

Tawil²

2022

JABB

View full text Add to dashboard Cite

Role of drug delivery technologies in the success of COVID-19 vaccines: a perspective

Cited by 32 publications

References 54 publications

Uncovering the information immunology journals transmitted for COVID-19: A bibliometric and visualization analysis

Uncovering the information immunology journals transmitted for COVID-19: A bibliometric and visualization analysis

Inhaled corticosteroids do not affect the antibody titer against the SARS-CoV-2 spike protein in BNT162b2 mRNA vaccinated patients

Development of the mRNA vaccines to prevent COVID-19

Contact Info

Product

Resources

About